Genetic Variations Do Not Account for Variable Response to Mycophenolate Mofetil in Lupus Nephritis
Wayne Kuznar, Noa Schwartz
Abstract
Wayne Kuznar, Noa Schwartz
Abstract
Genetic testing for variants of inosine monophosphate dehydrogenase isoforms will not predict clinical response to mycophenolate mofetil (MMF) in the treatment of lupus nephritis. The Study of Mycophenolate Mofetil in Management of Patients with Lupus Nephritis [ALMS] demonstrated the efficacy of MMF for induction and maintenance of response in lupus nephritis, but response was not uniform, leading to a search for predictors of efficacy.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Genetic testing for variants of inosine monophosphate dehydrogenase isoforms will not predict clinical response to mycophenolate mofetil (MMF) in the treatment of lupus nephritis. The Study of Mycophenolate Mofetil in Management of Patients with Lupus Nephritis [ALMS] demonstrated the efficacy of MMF for induction and maintenance of response in lupus nephritis, but response was not uniform, leading to a search for predictors of efficacy.
Key concepts: Mycophenolate, Lupus nephritis, Mycophenolic acid, Medicine, Systemic lupus erythematosus, Immunology, Nephritis, Internal medicine